scholarly journals Co-administering Melatonin With an Estradiol-Progesterone Menopausal Hormone Therapy Represses Mammary Cancer Development in a Mouse Model of HER2-Positive Breast Cancer

2019 ◽  
Vol 9 ◽  
Author(s):  
Balasunder R. Dodda ◽  
Corry D. Bondi ◽  
Mahmud Hasan ◽  
William P. Clafshenkel ◽  
Katie M. Gallagher ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mouse Model ◽  
Hormone Therapy ◽  
Mammary Cancer ◽  
Menopausal Hormone Therapy ◽  
Cancer Development ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Tissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer

2014 ◽  
Vol 35 (24) ◽  
pp. 3463-3469 ◽  
Author(s):  
Adam C. Searleman ◽  
Anton B. Iliuk ◽  
Timothy S. Collier ◽  
Lewis A. Chodosh ◽  
W. Andy Tao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mouse Model ◽  
Transgenic Mouse ◽  
Therapeutic Targets ◽  
Transgenic Mouse Model ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer

2017 ◽  
Vol 19 (1) ◽  
Author(s):  
Darcie D. Seachrist ◽  
Steven T. Sizemore ◽  
Emhonta Johnson ◽  
Fadi W. Abdul-Karim ◽  
Kristen L. Weber Bonk ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mouse Model ◽  
Metastasis Suppressor ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Risk factors associated with mortality among women with breast cancer in Haiti.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e13069-e13069
Author(s):  
Joseph Bernard ◽  
Garvey Rama Pascal ◽  
Sarah Cassandra Raymond ◽  
Vincent DeGennaro
Keyword(s):  
Breast Cancer ◽  
Hormone Therapy ◽  
Triple Negative ◽  
Stage Iii ◽  
Her2 Positive ◽  
Haitian Women ◽  
Factors Associated ◽  
Her2 Positive Breast Cancer ◽  
Er Positive ◽  
Positive Breast Cancer

e13069 Background: According to recent estimations of GLOBOCAN 2012, breast cancer is the 2ndmost common cancer among Haitian women. This study aims to describe the epidemiology of breast cancer at a Haitian hospital and to determine the factors associated with mortality. Methods: A retrospective chart review was conducted on women treated for breast cancer at the Innovating Health International Cancer Center, in Port-au-Prince, Haiti. All charts with complete information from 2014 and 2015 were included. Charts were reviewed to collect key variables related to breast cancer. Odds ratios were calculated and Mantel-Haenszel Chi-square test was used to identify the factors associated with mortality. Results: Among the 289 charts reviewed, 275 were selected for this study. The mean age is 51.82 years-old [20 - 100]. 81.1% of the patients had stage III or IV breast cancer at their first consultation. 92% of the women were diagnosed with invasive ductal carcinoma. Of the 165 cases tested for hormone receptor status, 54.5% were ER-positive, 31.5% were triple negative and 12.1% were HER2-enriched. The mortality rate is 24.4%. The odds of dying from breast cancer was significantly higher among women who had their menarche before 15 years old [Odds Ratio (OR) = 4.2; P = 0.02], stage III or IV breast cancer (OR = 3.7; P = 0.01), triple-negative or HER2-positive breast cancer (OR = 2.5; P = 0.01). Mortality was significantly lower among women who benefited from hormone therapy (OR = 0.22; P < 0.01). Conclusions: Breast cancer is often diagnosed at late stages in Haiti, which increases mortality. Women with ER-positive breast cancer survive significantly more than those with HER2-positive or triple-negative breast cancer, mainly due to the availability of hormone therapy and the absence of trastuzumab. A national awareness and screening program has to be implemented to educate Haitian women on breast cancer and increase early diagnosis. As an essential medicine in oncology according to the World Health Organization (WHO), biosimilar trastuzumab needs to be available to increase the survival of patients with HER2-positive breast cancer.

Sign in / Sign up

Export Citation Format

Share Document